ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Tandem Diabetes Care, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation - TNDM

Group 1 - The Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information [2] - Investors who purchased Tandem Diabetes Care securities may be entitled to compensation through a class action without any out-of-pocket fees [3] - On August 7, 2025, Tandem Diabetes Care announced a voluntary medical device correction for select t:slim X2 insulin pumps, leading to a 19.9% drop in stock price on the same day [4] Group 2 - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [5] - The firm has achieved significant settlements for investors, including over $438 million in 2019 and has been consistently ranked among the top firms in securities class action settlements [5]